Aeglea BioTherapeutics Doses First Patient in Phase 3 Trial of Pegzilarginase in Arginase 1 Deficiency

Aeglea BioTherapeutics (NASDAQ:AGLE) has announced the first patient in its Phase 3 PEACE trial has been dosed. As quoted in...

Biotech Trends 2018: Immuno-oncology Disappoints

2018 marked another critical year of growth for the biotech market. Learn about key biotech trends before the new year...

Aeglea BioTherapeutics Announces Design of Pivotal Phase 3 PEACE Trial Evaluating Pegzilarginase in Arginase 1 Deficiency

Aeglea BioTherapeutics (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic...

Aeglea BioTherapeutics Announces Positive Clinical Update

Aeglea BioTherapeutics issued an update on Tuesday for its ongoing Phase 1/2 trial of pegzilarginase in patients with a rare...

Aeglea BioTherapeutics Announces Positive Interim Clinical Data and Completion of Enrollment for Ongoing Phase 1/2 Trial of Pegzilarginase

Aeglea BioTherapeutics (NASDAQ: AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare...